demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID 19 outpatients
antiviral and associated therapy
azithromycin Hinks ... PRINCIPLE ACTION
chloroquine and derivatives ALBERTA HOPE-Covid19
hydroxychloroquine COVID-PEP Severity ... Q-PROTECT -HCQ alone BCN PEP-CoV-2-Study 2 ... COMIHY Reis ... NCT04597775 PATCH Cohort 1 ... COPE – Coalition V
fluvoxamine COVID-OUT ... TOGETHER ACTIV-6 Lenze ...
hydroxychloroquine plus macrolides NCT04621461
azithromycin plus hydroxychloroquine Q-PROTECT ... Q-PROTECT -AZI ... Rodrigues
ivermectin ACTIV-6 ... Podder Chahla Chaccour TOGETHER ... Buonfrate ... IVERCORCOVID19 ... Lopez-Medina ACTIV 6 ivermectin COVID-OUT ...
ivermectin plus doxycycline Chowdhury A
lopinavir/ritonavir Reis ...
molnupiravir Fischer ... MOVe-OUT
nirmatrelvir / ritonavir (Paxlovid) EPIC-HR
nitazoxanide RM08-3008 ...
remdesivir PINETREE ...
sofosbuvir and daclatasvir Roozbeh
umifenovir (arbidol) Ramachandran
zinc Thomas ...

3 studies excluded by filtering options 1

6381 Espitia-Hernandez, 2020 1310not a RCTrisk of bias not avaialble
6381 Espitia-Hernandez, 2020 1310not a RCTrisk of bias not avaialble
6625 Nasir, 2020 2310excludednot a RCTrisk of bias not avaialble